BMS 986156

Drug Profile

BMS 986156

Alternative Names: BMS-986156

Latest Information Update: 14 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics
  • Mechanism of Action TNFRSF18 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 02 Jun 2017 Adverse events data from a phase I/IIa trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Oct 2015 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Canada (unspecified route) (NCT02598960)
  • 01 Oct 2015 Phase-I/II clinical trials in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease) in Canada (unspecified route) (NCT02598960)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top